CAPR Earnings Prediction
The chart below shows how CAPR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CAPR sees a +3.06% change in stock price 10 days leading up to the earnings, and a +21.90% change 10 days following the report. On the earnings day itself, the stock moves by -0.77%. This data can give you a slight idea of what to expect for the next quarter's release.
CAPR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
2.26M
-63.44%
-43.05%
Gross Margin
--
--
--
Operating Margin
-575.24%
418.37%
97.09%
Net Margin
-555.20%
437.41%
100.45%
EPS
-0.38
-52.00%
8.57%
No Data Available
CAPR Earnings Analysis
Capricor Therapeutics Inc Corporation (CAPR.O) Earnings Conference Call
Positive
Revenue Comparison Q3 2023-2024: In the third quarter of 2024, Capricor reported revenues of approximately $2.3 million, a significant increase from approximately $6.2 million in the same quarter of 2023.
Public Offering Success: The company completed a public offering of common stock, raising approximately $86 million, which strengthens its cash position to approximately $165 million as of September 30, 2024.
Strong Cash Position: Capricor's cash and cash equivalents, along with marketable securities, totaled approximately $166 million, providing a strong runway into 2027.
Regulatory Progress for Approval: The company has made significant strides in its regulatory pathway, getting closer to potential approval of its lead product, deramciclus, for treating DMD.
Product Launch Preparation: Capricor is actively preparing for the launch of its product, with a strong focus on scaling manufacturing capabilities to meet anticipated demand.
Negative
Revenue Decline Analysis: Revenues for the third quarter of 2024 were approximately $2.3 million compared to approximately $6.2 million for the third quarter of 2023, indicating a significant decline in revenue.
Increased Net Loss: Net loss for the third quarter of 2024 was approximately $12.6 million compared to a net loss of approximately $6.4 million for the third quarter of 2023, reflecting worsening financial performance.
Operating Expense Increase: Operating expenses for the third quarter of 2024, excluding stock-based compensation, were approximately $11 million compared to approximately $9.5 million in Q3 2023, showing increased costs.
Rising R&D Expenses: Research and development expenses increased to approximately $11 million in Q3 2024 from approximately $9.5 million in Q3 2023, indicating rising investment without corresponding revenue growth.
Public Offering Proceeds: The company completed a public offering raising approximately $80.8 million in net proceeds, which may indicate a need for additional capital due to financial strain.
CAPR FAQs
How does CAPR typically perform around its earnings report dates?
Is Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CAPR Earning Call Sentiment
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CAPR.O
-7.66%Positive
The earnings call summary presents mixed signals. The financial performance shows a significant revenue decline and increased losses, which is concerning. However, the strong cash position and potential milestone payments from a European agreement are positive. The Q&A section highlights readiness for market launch and manufacturing capabilities, but there are uncertainties in trial designs and management responses. The public offering and cash position are positive, but the revenue decline and increased expenses dampen the overall sentiment, leading to a neutral prediction with potential for positive movement if milestones are achieved.
